AstraZeneca's Product Gefurulimab

Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26. 

Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints.

Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living, total score at week 26 compared to placebo . . .